What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Multiple myeloma
His primary areas of investigation include Multiple myeloma, Internal medicine, Surgery, Gastroenterology and Monoclonal gammopathy of undetermined significance.
The Multiple myeloma study combines topics in areas such as Clinical trial, Disease, Bone marrow and Pathology.
His Internal medicine study frequently draws connections between adjacent fields such as Oncology.
The Oncology study which covers Plasmacytoma that intersects with Macroglobulinemia.
His Gastroenterology research is multidisciplinary, incorporating perspectives in Chemotherapy, Hazard ratio, Myeloma protein, Survival analysis and Risk factor.
His Monoclonal gammopathy of undetermined significance research is multidisciplinary, relying on both Malignancy, Immunofixation, Proteinuria and Confidence interval.
His most cited work include:
- A phase 2 study of bortezomib in relapsed, refractory myeloma. (2325 citations)
- Improved survival in multiple myeloma and the impact of novel therapies (1718 citations)
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
What are the main themes of his work throughout his whole career to date?
S. Vincent Rajkumar spends much of his time researching Internal medicine, Multiple myeloma, Oncology, Gastroenterology and Surgery.
His study in Lenalidomide, Dexamethasone, Bortezomib, Transplantation and Amyloidosis falls under the purview of Internal medicine.
Immunofixation is closely connected to Monoclonal gammopathy of undetermined significance in his research, which is encompassed under the umbrella topic of Multiple myeloma.
When carried out as part of a general Oncology research project, his work on Progression-free survival is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His Gastroenterology study combines topics in areas such as Hazard ratio, Survival rate, Primary systemic amyloidosis, Myeloma protein and Survival analysis.
Surgery connects with themes related to Cohort in his study.
He most often published in these fields:
- Internal medicine (64.11%)
- Multiple myeloma (62.08%)
- Oncology (25.32%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (64.11%)
- Multiple myeloma (62.08%)
- Oncology (25.32%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Multiple myeloma, Oncology, Gastroenterology and AL amyloidosis.
His Amyloidosis, Dexamethasone, Ixazomib and Bortezomib study in the realm of Internal medicine interacts with subjects such as In patient.
He works in the field of Multiple myeloma, namely Lenalidomide.
S. Vincent Rajkumar has included themes like Hematopoietic stem cell transplantation, Stem cell and Daratumumab in his Oncology study.
The various areas that he examines in his Gastroenterology study include Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, Bone marrow and Hazard ratio.
His AL amyloidosis research incorporates elements of Retrospective cohort study, Family medicine and Urology.
Between 2017 and 2021, his most popular works were:
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. (156 citations)
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (136 citations)
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders (91 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
S. Vincent Rajkumar mainly investigates Internal medicine, Multiple myeloma, Oncology, Amyloidosis and Lenalidomide.
His study ties his expertise on Gastroenterology together with the subject of Internal medicine.
His research in Multiple myeloma intersects with topics in Clinical trial and Transplantation.
His biological study deals with issues like Hematopoietic stem cell transplantation, which deal with fields such as Survival analysis.
His Amyloidosis study also includes
- AL amyloidosis which intersects with area such as Bone marrow, Survival rate and Urology,
- Immunoglobulin light chain which is related to area like Immunofixation.
As a part of the same scientific study, he usually deals with the Lenalidomide, concentrating on Randomized controlled trial and frequently concerns with MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
